Chugai Ups Forecast On Star Performer Hemlibra
Roche affiliate substantially raises full-year forecast following double-digit sales and profit growth, mainly on the back of strength for hemophilia drug Hemlibra.
You may also be interested in...
Japanese firm unveils major restructuring of R&D sites in Japan through a new $1bn core lab set to open in early 2023 and the closure of two other long-established facilities.
Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.